BridgeBio Pharma, Inc. (BBIO)

NASDAQ: BBIO · Real-Time Price · USD

65.48

+1.60 (2.50%)

At close: Jun 3, 2026, 4:00 PM EDT

62.63

-2.86 (-4.36%)

After-hours: Jun 3, 2026, 5:28 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Product Revenue	506.23M	362.37M	2.88M
Net Product Revenue Growth	39.70%	12464.77%	-99.20%
License and Services Revenue	53.05M	128.32M	218.85M
License and Services Revenue Growth	-58.66%	-41.37%	-
Royalty Revenue	20.68M	11.39M	169.00K
Royalty Revenue Growth	81.64%	6637.28%	-98.49%
Revenue (Total)	579.96M	502.08M	221.90M
Revenue (Total) Growth	15.51%	126.26%	2285.27%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
U.S. - Geographic Revenue Distribution	72.20%	6.00%
Europe, Middle East, and Africa (EMEA) - Geographic Revenue Distribution	25.30%	59.50%
Asia-Pacific (APAC) - Geographic Revenue Distribution	2.50%	34.50%

Updated May 7, 2026. Data Source: Fiscal.ai.